Financial Results

News & Events

Inventiva to present new results of its YAP-TEAD oncology program at the AACR Special Conference on The Hippo Pathway

23 April 2019

Daix (France), April 23, 2019 – Inventiva (Euronext: IVA), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal storage disorders and oncology, today announced that the abstract on the evaluation of its YAP-TEAD Protein-Protein Interaction inhibitors for treating Malignant Pleural Mesothelioma (MPM) submitted to the American Association for Cancer Research (AACR) has been accepted for a poster presentation at the upcoming AACR Special Conference on The Hippo Pathway: Signaling, Cancer, and Beyond (May 8-11, 2019, San Diego, California).

The study, which aimed at supporting a multi-pronged approach to treat MPM, will be presented by Anne Soudé, Senior Scientist in charge of the YAP-TEAD program at Inventiva. Amongst other results, the study showed that Inventiva’s YAP-TEAD inhibitors significantly reduced tumor growth in MPM xenograft and orthotopic models. In addition, synergistic effects were seen in a three dimensional spheroid modelsuggesting that the Company’s YAPTEAD inhibitors, when used in combination with existing chemotherapeutics, could attenuate multidrug resistance and re-sensitize chemo-resistant cancer cells.

Following these promising results, Inventiva has decided to expand its studies to other cancer indications as well as other combination strategies where standard of care agents are proven to be ineffective and where YAP is activated. Moreover, Inventiva is planning to study the capacity of its compounds to overcome immune evasion, another common challenge in treating cancer where the tumor is not recognized and eliminated by the immune system.

Pierre Broqua, Chief Scientific Officer and cofounder of Inventiva, commented: “These new results reinforce the rationale that our YAP-TEAD inhibitors could constitute a relevant approach to treat mesothelioma. We are particularly excited by the potential of our compounds to attenuate drug resistance in several cancers through an efficacious combination with standard of care. We are currently in the process of selecting a drug candidate for our oncology program and look forward to entering its pre-clinical development later this year.”

The abstract, which is entitled “Discovery of YAP-TEAD Protein-Protein Interaction inhibitors (PPI) for treating Malignant Pleural Mesothelioma (MPM)”, will be presented on Friday, May 10, 2019.

The details of the presentation are as follows:
Abstract title: “Discovery of YAP-TEAD Protein-Protein Interaction inhibitors (PPI) for treating Malignant Pleural Mesothelioma (MPM)”
Session: Poster Session B
Speaker: Anne Soudé, Senior Scientist in charge of target identification and validation, Inventiva
Date: Friday, May 10, 2019
Time: 12:30 pm – 2:30 pm (Pacific Daylight Time)
Location: Marriott Marquis San Diego Marina hotel, San Diego, California
Event: “AACR Special Conference on The Hippo Pathway: Signaling, Cancer, and Beyond”

About the YAP-TEAD program

The YAP-TEAD program aims to disrupt the interaction between yes-associated protein, or YAP, and transcription enhancer associated domain transcription factors, or TEAD, which occurs along the Hippo signaling pathway and which plays a key role in the oncogenic process. The Hippo signaling pathway is involved in the processes of cell differentiation and proliferation, tissue growth and organ size. Dysregulation along the Hippo signaling pathway has been associated with drug resistance, immune evasion, tumor growth and metastases. A great variety of cancers, particularly malignant mesothelioma, as well as lung cancer, triple negative breast cancer, hepatocellular carcinoma and hepatoblastoma, as well as fibrotic diseases, are displaying a dysfunction of the Hippo pathway.

In pre-clinical studies, Inventiva’s compounds prevented the formation of the YAP/TEAD transcriptional complex, reduced the expression of YAP/TEAD target genes and displayed anti-proliferative effects in cancer cell lines the proliferation of which is controlled by the Hippo signaling pathway, both as a monotherapy and in combination with approved cancer therapies. Furthermore, in xenograft models of Malignant Pleural Mesothelioma (MPM), the compounds produced significant tumor regression after oral administration.

Inventiva is currently in the process of selecting a clinical drug candidate for its oncology program, which it anticipates entering pre-clinical development later this year.


Frédéric Cren

Chief Executive Officer
+33 3 80 44 75 00


Aude Hillion/ Yannick Tetzlaff
Media relations
+33 1 53 96 83 83

LifeSci Advisors
Monique Kosse

Investor relations

About Inventiva
Inventiva is a biopharmaceutical company specialized in the development of drugs interacting with nuclear receptors, transcription factors and epigenetic modulators. Inventiva’s research engine opens up novel breakthrough therapies against fibrotic diseases, cancers and orphan diseases with substantial unmet medical needs.

Lanifibranor, its lead product, is an anti-fibrotic treatment acting on the three alpha, gamma and delta PPARs (peroxisome proliferator-activated receptors), which play key roles in controlling the fibrotic process. Its anti-fibrotic action targets two initial indications with substantial unmet medical need: NASH, a severe and increasingly prevalent liver disease already affecting over 30 million people in the United States, and systemic sclerosis, a disease with a very high mortality rate and for which there is no approved treatment to date.

Inventiva is also developing a second clinical program with odiparcil (IVA 336) for the treatment of patients with mucopolysaccaridosis type VI (or Maroteaux-Lamy syndrome), a rare and severe gene disease affecting children. Odiparcil has also the potential to address other MPS types, characterized by the accumulation of chondroitin or dermatan sulfate (MPS I or Hurler/Sheie syndrome, MPS II or Hunter syndrome, MPS IVa or Morquio syndrome and MPS VII or Sly syndrome). Inventiva is also developing a portfolio of early research projects in the field of oncology.

Inventiva benefits from partnerships with world-leading research entities such as the Institut Curie in the field of oncology. Two strategic partnerships have also been established with world-class major pharmaceutical companies AbbVie and Boehringer Ingelheim in the fields of autoimmune diseases (specifically in psoriasis) and fibrosis respectively. These partnerships provide milestone payments to Inventiva upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on the products resulting from the partnerships.

Inventiva employs over 100 employees and owns R&D facilities near Dijon, acquired from the international pharmaceutical group Abbott. The Company owns, a proprietary chemical library of over 240,000 molecules as well as integrated biology, chemistry, ADME and pharmacology platforms.

Important Notice
This press release contains forward-looking statements, forecasts and estimates with respect to the clinical development
plans, business and regulatory strategy, and anticipated future performance of Inventiva and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management”s beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva”s control.

There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.

Please refer to the “Document de référence” filed with the Autorité des Marchés Financiers on April 13, 2018 under n° R.18-013 for additional information in relation to such factors, risks and uncertainties.

Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements.